Status:
WITHDRAWN
Prevention and Treatment of Hemodialysis Vascular Access Malfunction
Lead Sponsor:
Vanderbilt University
Conditions:
End-Stage Renal Disease
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
Vascular access is considered the Achilles heel of the dialysis patient. It constitutes the largest single cause of morbidity in the chronic hemodialysis population, accounting for over 25% of hospita...
Eligibility Criteria
Inclusion
- Subjects with End Stage Renal Disease on chronic maintenance hemodialysis 3 times per week
- Have an arteriovenous (polytetrafluoroethylene) graft as vascular access
- Have a venous stenosis between 30% and 70% as determined by angiogram
Exclusion
- Native arteriovenous fistula
- Known previous vascular accesses complications, such as central vein stenosis, and multiple access surgeries \>4
- Unwilling to participate
- Allergy to iodine
- Absolute contraindication for surgery (e.g. medical condition precludes anesthesia and surgery)
- Known arterial limb stenosis or long vessel length venous stenosis which are unamenable to surgical or angioplasty techniques, respectively, and therefore prohibit randomization
- Known hypercoagulable state
Key Trial Info
Start Date :
May 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00179192
Start Date
May 1 1998
End Date
October 1 2006
Last Update
May 25 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232